IP Verse

Liquid Pharmaceutical Composition - EP3145487

The patent EP3145487 was granted to Ares Trading on Aug 22, 2018. The application was originally filed on May 15, 2015 under application number EP15722541A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3145487

ARES TRADING
Application Number
EP15722541A
Filing Date
May 15, 2015
Status
Granted And Under Opposition
Jul 20, 2018
Publication Date
Aug 22, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMGEN EUROPEDec 20, 2018BIRD & BIRDWITHDRAWN

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2010278822
INTERNATIONAL-SEARCH-REPORTWO2013011076
INTERNATIONAL-SEARCH-REPORTWO2014039903
OPPOSITIONCN104707146
OPPOSITIONEP3085385
OPPOSITIONUS2009291062
OPPOSITIONUS2014086930
OPPOSITIONUS2014141007
OPPOSITIONUS5900404
OPPOSITIONWO2005072772
OPPOSITIONWO2006131013
OPPOSITIONWO2009076105
OPPOSITIONWO2012089778
OPPOSITIONWO2013006454
OPPOSITIONWO2013164837
OPPOSITIONWO2014071212
OPPOSITIONWO2015177057
OPPOSITIONWO9729131

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- ANDYA, "The effect of sugars and buffer excipients on the stabilization of a lyophilized formulation for an anti-IgE humanized monoclonal antibody", Pharmaceutical Research, (19960000), vol. 13, no. 9, page S78, XP055543010
OPPOSITION- Anonymous, "Golimumab for the Treatment of Rheumatoid Arthritis after Failure of Previous Disease-Modifying Antirheumatic Drugs", (20100702), pages 1 - 361
OPPOSITION- "Buffer reference center", Sigma-Aldrich Homepage, (20140423), URL: www.sigmaaldrich.com/life-science /core-bioreagents/biological-buffers/learning-center/buffer-reference-center.html
OPPOSITION- HAWE, "Fluorescent Molecular Rotors as Dyes to Characterize Polysorbate-Containing IgG Formulations", Pharmaceutical Research, (20100000), vol. 27, no. 2, pages 314 - 326, XP019773697
OPPOSITION- "Humira Highlights of prescribing information", HUMIRA Label - FDA, (20080100), pages 1 - 34, XP055543024
OPPOSITION- "HUMIRA Product information", (20110321), pages 1 - 38, XP055543016
OPPOSITION- SINGH et al., "Best practices for formulation and manufacturing of biotech drug products", BioPharm International, (20090600), vol. 22, pages 32 - 48, XP055543037
OPPOSITION- Steven E RUZIN, "Buffers", Plant Microtechnique and Microscopy, Oxford University Press, pages 223 - 235, XP055542962
OPPOSITION- JAIN, "Trehalose and Protein Stability", Current Protocols in Protein Science, (20100000), pages 4.9.1 - 4.9.12, XP055145633
OPPOSITION- MATHEUS, "A Critical Evaluation of Tm(FTIR) Measurements of High-Concentration IgG1 Antibody Formulations as a Formulation Development Tool", Pharmaceutical Research, (20060000), vol. 23, no. 7, pages 1617 - 1627, XP019405151
OPPOSITION- PIEDMONTE et al., Pharmaceutical Research, (20060000), vol. 2, pages 136 - 146, XP019453341
OPPOSITION- WARNE, "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", European Journal of Pharmaceutics and Biopharmaceutics, (20110000), vol. 78, pages 280 - 211, XP055534222
OPPOSITION- FRENKEN et al., "Identification of the Component Part in an Epoetin Alfa Preparation That Causes Pain After Subcutaneous Injection", Am. J. Kidney Diseases, (19930000), vol. 22, no. 4, pages 553 - 556, XP055393258
OPPOSITION- RATHORE et al., "Current Perspectives on Stability of Protein Drug Products during Formulation, Fill and Finish Operations", Biotechnol. Prog., (20080000), vol. 24, no. 3, pages 5 04 - 514, XP055155930
OPPOSITION- CAVATUR et al., "Crystallization Behavior of Mannitol in Frozen Aqueous Solutions", Pharmaceutical Research, (20020600), vol. 19, no. 6, pages 894 - 899, XP055543032
OPPOSITION- LAURSEN et al., "Pain Perception after Subcutaneous Injections of Media Containing Different Buffers", Basic & Clinical Pharmacology & Toxicology, (20060000), vol. 98, no. 2, pages 218 - 221, XP055118277
OPPOSITION- FRANSSON et al., "Local Tolerance of Subcutaneous Injections", J. Pharm. Pharmacol., (19960000), vol. 48, pages 1012 - 1015, XP055364940
OPPOSITION- S. SAITO, "Development of a general strategy for formulation optimization of therapeutic monoclonal antibodies Doctoral Dissertation", Osaka University, (20130700), pages FP - 117, XP055542993

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents